How Fast Can AI Answer a Commercial Question Compared to Traditional Market Research?

A traditional custom analysis typically takes four to eight weeks from scoping to report. An AI-powered insight platform working on integrated real-world data returns first answers in one to five minutes. The gap is not incremental efficiency; it changes which questions get asked at all, and that behavioral shift is where the commercial advantage lives.

Where the eight weeks go

The slowness of traditional market research is not laziness; it is structure. A focused question gets scoped into a larger project because minimum budgets require it. Briefing loops align consultants with context they do not have. Analysis, quality control, and report production each add their share. The result arrives polished, static, and often after the decision window has narrowed or closed.

Follow-up questions restart the cycle. Anything complex gets re-scoped. Anyone who has watched a sharp question turn into a three-month engagement recognizes the pattern.

Where the minutes come from

The AI model removes the queue, not the rigor. The data is already integrated and continuously updated: longitudinal prescription journeys, claims, patient-reported sources. The analytical work is done by the system at question time. Ask about 12-month persistence for new versus switch patients in a specific region, or how first-line patient share has evolved, and the analysis runs on demand. Follow-ups cost minutes, not re-scoping meetings.

With Permea Research Mode, that is the working reality: first insights in one to five minutes, self-service, with expert support optional rather than mandatory.

Why speed compounds

When a question costs eight weeks, organizations ration questions. Hypotheses go untested because testing is expensive, and strategy calcifies around the few insights that survived the process. When a question costs minutes, teams test more hypotheses, kill weak ones faster, and compound the strong ones.

The launch window shows the stakes most clearly: industry analysis of US drug launches finds that first-year performance strongly predicts the following two years, which means the weeks spent waiting for a custom analysis during launch are the most expensive weeks a brand will ever lose. And the questions that benefit most are the small ones, too small to scope, too important to skip, that the old economics silently killed.

Speed without judgment is noise, of course. Fast answers still pass through validation proportional to the decision. But the sequencing changes: validate the answers that matter, instead of waiting weeks to see any answer at all.

The most expensive analysis is the one that arrives after the decision. The Permea Insight Hub answers commercial questions from real-world patient data in minutes, so your team decides while the window is still open.

→ Explore the Permea Insight Hub